If such pills catch on, they could generate significant revenues for drug companies. In Pfizer's ease, the goal is to transfer as many qualified patients as possible to the combo pill. Norvasc's patents expire in 2007, but Pfizer could avoid losing all its revenues from the drug at once if it were part of a superpill. Sena Lund, an analyst at Cathay Financial, sees Pfizer selling $4.2 billion worth of Norvasc-Lipitor by 2007. That would help take up the slack for falling sales of Lipitor, which he projects will drop to $5 billion in 2007, down from $8 billion last year.
Pfizer argues that addressing two distinct and serious cardiovascular risk factors in one pill has advantages. People with both hypertension and high LDL cholesterol (the "bad" kind) number around 27 million in the U.S., notes Craig Hopkinson, medical director for dual therapy at Pfizer, and only 2% of that population reaches adequate treatment goals. Taking two treatments in one will increase the number of patients who take the medications properly and "assist in getting patients to goal", be says.
Doctors also may be quick to adopt Norvasc-Lipitor, Pfizer figures, because it's made up of two well-studied drugs, which many physicians are already familiar with. But Dr. Stanley Rockson, chief of consultative cardiology at Stanford University Medical Center, says fixed-dose combination pills represent "an interesting crossroads" for physicians, who are typically trained to "approach each individual problem with care". Combining treatments would challenge doctors to approach heart disease differently. But better patient compliance is important enough, says Rockson, that he expects doctors, to be open to trying the combined pill.
Some other physicians are more skeptical. "If you want to change dosage on one of the new pill's two drugs, you're stuck", fears Dr. Irene Gavris, professor of medicine at Boston University School of Medicine. She says she would feel most comfortable trying the combination pill on patients who "have been on the drugs for a while" and are thus unlikely to need changes in dosage.
As usual, economics could tip the scales. Patients now taking both Lipitor and Norvasc "could cut their insurance co pay in half" by switching to the combo drug, Gavris notes. That's a key advantage. Controlling hypertension, for instance, can require three or more drugs, and the financial burden on patients mounts quickly. If patients also benefit—as Pfizer and other drug companies contend—making the switch to superpills could be advantageous for everyone.
Pfizer could avoid the loss caused by expiration of Norvasc's patents by ______.
A.reducing the various risks to heart health
B.switching the patients to the superpills
C.offering greater convenience to patients
D.increasing the sales of Lipitor
第1题
某公司进口货物一批,CIF(到岸价)成交价格为人民币600万元,含单独计价并经海关审核属实的进口后装配调试费用50万元,该货物进口关税税率为10%,根据海关填发税款缴纳证日期推算最后日期为1月24日,该公司于1月25日交纳税款。则该公司应纳关税滞纳金为()元。
第2题
A.185
B.275
C.280
D.291
第3题
A.329
B.285
C.570
D.658
第4题
一、目的:练习滞纳金的计算。
二、资料:
进口货物一批,CIF(到岸价格)成交价格为人民币1000万元,含单独计价并经海关审核属实的进口后装配调试费用200万元,该货物进口关税税率为10%,海关填发税款缴纳证日期为2008年3月7日,该公司于3月25日缴纳税款。
三、要求:计算应纳关税和滞纳金。
第5题
A.单独计价的进口后装配调试费用不计入进口货物关税的完税价格
B.单独计价的进口后装配调试费用应计入进口货物关税的完税价格
C.该公司应纳关税和滞纳金60.24万元
D.该公司应纳关税和滞纳金57.23万元
第6题
A.单独计价进口后装配调试费用不计入进口货物关税的完税价格
B.单独计价进口后装配调试费用应计入进口货物关税的完税价格
C.该公司应纳关税和滞纳金60.24万元
D.该公司应纳关税和滞纳金57.23万元
第7题
A.单独计价的进口后装配调试费用不计入进口关税的完税价格
B.单独计价的进口后装配调试费用应计入进口关税的完税价格
C.该企业应纳关税和滞纳金60.24万元
D.该企业应纳关税和滞纳金57.23万元
第8题
A.单独计价的进口后装配调试费用不计入进口关税的完税价格
B.单独计价的进口后装配调试费用应计入进口关税的完税价格
C.该企业应纳关税和滞纳金60.24万元
D.该企业应纳关税和滞纳金57.23万元
第9题
为了保护您的账号安全,请在“上学吧”公众号进行验证,点击“官网服务”-“账号验证”后输入验证码“”完成验证,验证成功后方可继续查看答案!